185 related articles for article (PubMed ID: 31110830)
1. A Rare Case of Grey Zone Lymphoma Successfully Treated with Brentuximab Vedotin and R-CHP Chemotherapy.
Mallipudi RM; Alquran L; Shenoy VA; Leslie LA; Conti JA
Case Rep Oncol Med; 2019; 2019():4121234. PubMed ID: 31110830
[TBL] [Abstract][Full Text] [Related]
2. Brentuximab vedotin as a bridge to combination chemotherapy in gray zone lymphoma with severe liver impairment: a case report.
Asrani R; Cengiz TB; Petersen BE; Anagnostou T; Brody JD
Front Oncol; 2023; 13():1254256. PubMed ID: 38313213
[TBL] [Abstract][Full Text] [Related]
3. Brentuximab vedotin maintenance after autologous stem cell transplantation for refractory gray zone lymphoma with long-term remission.
Terao T; Yuda J; Yamauchi N; Guo YM; Shimada K; Sugano M; Ishii G; Minami Y
Mol Clin Oncol; 2021 Jun; 14(6):125. PubMed ID: 33936598
[TBL] [Abstract][Full Text] [Related]
4. Brentuximab vedotin plus AVD followed by involved-node radiotherapy in a patient with classic Hodgkin lymphoma following gray zone lymphoma after autologous stem-cell transplantation failure.
Ueda N; Kato H; Kato S; Saito T; Tachibana H; Yanada M; Taji H; Kodaira T; Hosoda W; Yamamoto K
Hematology; 2023 Dec; 28(1):2207946. PubMed ID: 37183912
[TBL] [Abstract][Full Text] [Related]
5. How I manage patients with grey zone lymphoma.
Kritharis A; Pilichowska M; Evens AM
Br J Haematol; 2016 Aug; 174(3):345-50. PubMed ID: 27301470
[TBL] [Abstract][Full Text] [Related]
6. Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas.
Svoboda J; Bair SM; Landsburg DJ; Dwivedy Nasta S; Nagle SJ; Barta SK; Khan N; Filicko-O'Hara J; Gaballa S; Strelec L; Chong E; Mitnick S; Waite TS; King C; Ballard H; Youngman M; Gerson J; Plastaras JP; Maity A; Bogusz AM; Hung SS; Nakamura H; Nejati R; Steidl C; Lim M; Ruella M; Schuster SJ
Haematologica; 2021 Jun; 106(6):1705-1713. PubMed ID: 32414850
[TBL] [Abstract][Full Text] [Related]
7. Gray zone lymphoma effectively treated with cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab chemotherapy: A case report.
Hojo N; Nagasaki M; Mihara Y
World J Clin Cases; 2022 Jun; 10(17):5708-5716. PubMed ID: 35979119
[TBL] [Abstract][Full Text] [Related]
8. Classical Hodgkin lymphoma primary refractory to brentuximab vedotin, with transformation to CD30-positive diffuse large B-cell lymphoma.
Makita S; Maeshima AM; Taniguchi H; Kitahara H; Fukuhara S; Munakata W; Suzuki T; Maruyama D; Kobayashi Y; Tobinai K
Int J Hematol; 2016 Sep; 104(3):396-9. PubMed ID: 27169615
[TBL] [Abstract][Full Text] [Related]
9. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
10. [Grey zone lymphoma with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: clinicopathologic characterization of 16 cases showing different patterns].
Wang L; Wang W; Li X; Guo Y; Zhu X
Zhonghua Bing Li Xue Za Zhi; 2014 May; 43(5):307-12. PubMed ID: 25030862
[TBL] [Abstract][Full Text] [Related]
11. Unraveling the Mystery of Gray Zone Lymphoma in Human Immunodeficiency Virus-Seropositive Patients: Two Cases.
Ahluwalia A; Bondili L; Salamera J; Cholankeril M
J Hematol; 2020 Dec; 9(4):132-136. PubMed ID: 33224393
[TBL] [Abstract][Full Text] [Related]
12. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.
Jacobsen ED; Sharman JP; Oki Y; Advani RH; Winter JN; Bello CM; Spitzer G; Palanca-Wessels MC; Kennedy DA; Levine P; Yang J; Bartlett NL
Blood; 2015 Feb; 125(9):1394-402. PubMed ID: 25573987
[TBL] [Abstract][Full Text] [Related]
13. New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.
Merli M; Ferrario A; Maffioli M; Olivares C; Stasia A; Arcaini L; Passamonti F
Expert Rev Hematol; 2016 Aug; 9(8):767-80. PubMed ID: 27416486
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL.
Pilichowska M; Pittaluga S; Ferry JA; Hemminger J; Chang H; Kanakry JA; Sehn LH; Feldman T; Abramson JS; Kritharis A; Hernandez-Ilizaliturri FJ; Lossos IS; Press OW; Fenske TS; Friedberg JW; Vose JM; Blum KA; Jagadeesh D; Woda B; Gupta GK; Gascoyne RD; Jaffe ES; Evens AM
Blood Adv; 2017 Dec; 1(26):2600-2609. PubMed ID: 29296913
[TBL] [Abstract][Full Text] [Related]
15. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.
Fanale MA; Horwitz SM; Forero-Torres A; Bartlett NL; Advani RH; Pro B; Chen RW; Davies A; Illidge T; Huebner D; Kennedy DA; Shustov AR
J Clin Oncol; 2014 Oct; 32(28):3137-43. PubMed ID: 25135998
[TBL] [Abstract][Full Text] [Related]
16. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin.
Oregel KZ; Everett E; Zhang X; Nagaraj G
Expert Rev Anticancer Ther; 2016; 16(3):279-83. PubMed ID: 26809026
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma.
Makita S; Maruyama D; Tobinai K
Onco Targets Ther; 2020; 13():5993-6009. PubMed ID: 32606807
[TBL] [Abstract][Full Text] [Related]
18. FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell Lymphoma.
Richardson NC; Kasamon YL; Chen H; de Claro RA; Ye J; Blumenthal GM; Farrell AT; Pazdur R
Oncologist; 2019 May; 24(5):e180-e187. PubMed ID: 30914464
[TBL] [Abstract][Full Text] [Related]
19. Durable Response to Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, and Prednisone (BV-CHP) in a Patient with CD30-Positive PTCL Arising as a Post-Transplant Lymphoproliferative Disorder (PTLD).
Hong J; Johnson WT; Kartan S; Gonsalves AS; Fenkel JM; Gong JZ; Porcu P
Curr Oncol; 2021 Dec; 28(6):5067-5072. PubMed ID: 34940065
[TBL] [Abstract][Full Text] [Related]
20. Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review.
Berger GK; McBride A; Lawson S; Royball K; Yun S; Gee K; Bin Riaz I; Saleh AA; Puvvada S; Anwer F
Crit Rev Oncol Hematol; 2017 Jan; 109():42-50. PubMed ID: 28010897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]